Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Corautus Genetics, Inc.
Atlanta, Georgia, United Statesbiopharmguy.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Corautus developed a gene therapy product candidate using the VEGF2 gene to promote therapeutic angiogenesis in ischemic muscle. The GENASIS Phase IIb trial for severe angina did not show significant separation from placebo. The company also supported early clinical trials in diabetic neuropathy and critical limb ischemia but shifted focus after disappointing results to seek new opportunities via merger or acquisition[9].
- Therapeutic areas
- CardiovascularEndocrinology
- Modalities
- Gene therapy (VEGF gene transfer)
- Industry
- Biotech
02
Partnerships
Boston Scientific Corporation—strategic alliance to develop, commercialize and distribute VEGF-based therapies[9]
Beyond the preview
Go deeper on Corautus Genetics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Corautus Genetics, Inc..